Avoro Capital leads Series B in Ethyreal Bio’s $101 million financing round

  • Ethyreal Bio raised USD 101 million in private financing to advance ETHY-001, an anti-TSHR monoclonal antibody for thyroid eye disease, Graves’ disease.
  • Series A was co-led by Atlas Venture, Medicxi Ventures; Nandi Life Sciences, Checkpoint Capital also participated.
  • Series B included prior investors, led by Avoro Capital Advisors LLC.
  • Ethyreal targets first-in-human trials in the second half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avoro Capital Advisors LLC published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.